Chescapmanager’s ALX Oncology ALXO Stock Holding History

Chescapmanager’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,613	Closed	-$307K	–	65
2021 Q2	$307K	Buy	+5,613	New	+$336K	0.03%	62

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Chescapmanager's ALXO Position: Q3 2021 in Review

Chescapmanager sold out of ALX Oncology (ALXO) in Q3 2021, closing a stake of 5,613 shares — an estimated $307K sold.

Chescapmanager first reported a position in ALXO in Q2 2021 and held it in 1 quarter. The position peaked at $307K in Q2 2021. 114 funds tracked by Wall St. Rank hold ALXO as of Q3 2021.

Chescapmanager reported no remaining ALX Oncology position as of Q3 2021 after selling out during the quarter.
Chescapmanager sold 5,613 ALX Oncology shares in Q3 2021, an estimated $307K.
Chescapmanager first reported a position in ALX Oncology in Q2 2021 and held it in 1 quarter.
Chescapmanager's ALX Oncology position peaked at $307K in Q2 2021.
114 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2021.

Based on Chescapmanager's 13F filing for Q3 2021, filed 15 Nov 2021.